BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
1 . A pharmaceutical composition comprising an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof and an effective amount of an additional anti-viral compound selected from a protease inhibitor, a NS5B polymerase inhibitor, and a NS5A inhibitor in a pharmaceutically acceptable carrier.
2 . The pharmaceutical composition of claim 1 comprising a compound of the formula:
or a pharmaceutically acceptable salt thereof.
3 . The pharmaceutical composition of claim 1 comprising a compound of the formula:
or a pharmaceutically acceptable salt thereof.
4 . The pharmaceutical composition of claim 1 , wherein the additional anti-viral compound is a protease inhibitor.
5 . The pharmaceutical composition of claim 4 , wherein the protease inhibitor is a NS3/4A protease inhibitor.
6 . The pharmaceutical composition of claim 1 , wherein the additional anti-viral compound is a NS5A inhibitor.
7 . The pharmaceutical composition of claim 1 , wherein the additional anti-viral compound is a NS5B polymerase inhibitor.
8 . The pharmaceutical composition of claim 1 , in an oral dosage form.
9 . The pharmaceutical composition of claim 8 , wherein the oral dosage form is a solid dosage form.
10 . The pharmaceutical composition of claim 9 , wherein the solid dosage form is a tablet or capsule.
11 . The pharmaceutical composition of claim 8 , wherein the oral dosage form is a liquid dosage form.
12 . The pharmaceutical composition of claim 11 , wherein the liquid dosage form is a suspension or solution.
13 . The pharmaceutical composition of claim 1 , in an intravenous formulation.
14 . The pharmaceutical composition of claim 1 , in a parenteral formulation.
15 . The pharmaceutical composition of claim 2 , wherein the additional anti-viral compound is a protease inhibitor.
16 . The pharmaceutical composition of claim 15 , wherein the protease inhibitor is a NS3/4A protease inhibitor.
17 . The pharmaceutical composition of claim 2 , wherein the additional anti-viral compound is a NS5A inhibitor.
18 . The pharmaceutical composition of claim 2 , wherein the additional anti-viral compound is a NS5B polymerase inhibitor.
19 . The pharmaceutical composition of claim 2 , in an oral dosage form.
20 . The pharmaceutical composition of claim 19 , wherein the oral dosage form is a solid dosage form.
21 . The pharmaceutical composition of claim 20 , wherein the solid dosage form is a tablet or capsule.
22 . The pharmaceutical composition of claim 19 , wherein the oral dosage form is a liquid dosage form.
23 . The pharmaceutical composition of claim 22 , wherein the liquid dosage form is a suspension or solution.
24 . The pharmaceutical composition of claim 2 , in an intravenous formulation.
25 . The pharmaceutical composition of claim 2 , in a parenteral formulation.
26 . The pharmaceutical composition of claim 3 , wherein the additional anti-viral compound is a protease inhibitor.
27 . The pharmaceutical composition of claim 26 , wherein the protease inhibitor is a NS3/4A protease inhibitor.
28 . The pharmaceutical composition of claim 3 , wherein the additional anti-viral compound is a NS5A inhibitor.
29 . The pharmaceutical composition of claim 3 , wherein the additional anti-viral compound is a NS5B polymerase inhibitor.
30 . The pharmaceutical composition of claim 3 , in an oral dosage form.
31 . The pharmaceutical composition of claim 30 , wherein the oral dosage form is a solid dosage form.
32 . The pharmaceutical composition of claim 31 , wherein the solid dosage form is a tablet or capsule.
33 . The pharmaceutical composition of claim 30 , wherein the oral dosage form is a liquid dosage form.
34 . The pharmaceutical composition of claim 33 , wherein the liquid dosage form is a suspension or solution.
35 . The pharmaceutical composition of claim 3 , in an intravenous formulation.
36 . The pharmaceutical composition of claim 3 , in a parenteral formulation.